Palvella Therapeutics (PVLA) Other Non Operating Income (2014 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Other Non Operating Income of -$32000.0 for Q1 2026, up 57.33% year-over-year from -$20339.0 in Q1 2025, and up 73.11% quarter-over-quarter from -$119000.0 in Q4 2025.
Powered by 
Analysis
Palvella Therapeutics (PVLA) Other Non Operating Income (2014 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Other Non Operating Income for 13 consecutive years, with -$32000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 57.33% year-over-year to -$32000.0; the TTM figure through Mar 2026 stood at $328000.0 (down 12.06% YoY), while the FY2025 annual figure was -$394000.0, changed N/A from the prior year.
- Other Non Operating Income improved to -$32000.0 in Q1 2026 per PVLA's latest filing, from -$119000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $723000.0 in Q3 2022 and bottomed at -$325000.0 in Q4 2022.
- Historically, Other Non Operating Income has averaged $156352.9 across 5 years, with a median of -$20000.0 in 2024.
- On a YoY basis, Other Non Operating Income climbed as much as 776.56% in 2025 and fell as far as 310.0% in 2025.
- Palvella Therapeutics' Other Non Operating Income stood at -$325000.0 in 2022, then surged by 230.46% to $424000.0 in 2023, then fell by 4.72% to $404000.0 in 2024, then tumbled by 129.46% to -$119000.0 in 2025, then soared by 73.11% to -$32000.0 in 2026.
- Business Quant data shows PVLA's Other Non Operating Income at -$32000.0 in Q1 2026, -$119000.0 in Q4 2025, and -$82000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -114,000.00 |
| Mar 31, 2026 | -116,000.00 |
| Dec 31, 2025 | -92,000.00 |
| Sep 30, 2025 | -82,000.00 |
| Jun 30, 2025 | 561,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Dec 31, 2024 | -229,000.00 |
| Sep 30, 2024 | -75,000.00 |
| Jun 30, 2024 | -271,000.00 |
| Mar 31, 2024 | -58,000.00 |
| Dec 31, 2023 | 424,000.00 |
| Sep 30, 2023 | 506,000.00 |
| Jun 30, 2023 | -161,000.00 |
| Mar 31, 2023 | -57,000.00 |
| Dec 31, 2022 | -325,000.00 |
| Sep 30, 2022 | 723,000.00 |
| Jun 30, 2022 | 676,000.00 |
| Mar 31, 2022 | 229,000.00 |
| Dec 31, 2021 | 378,000.00 |
| Sep 30, 2021 | 678,000.00 |